Evidence map›Paper›PMID 27758931›Full record

ArticleThe Journal of pharmacology and experimental therapeutics2016

Impact of Substrate-Dependent Inhibition on Renal Organic Cation Transporters hOCT2 and hMATE1/2-K-Mediated Drug Transport and Intracellular Accumulation.

Jia Yin, Haichuan Duan, Joanne Wang

Open access · bronzeAbstract read
In one paragraph

Article in The Journal of pharmacology and experimental therapeutics, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed
3.0field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

22 citing papers in PubMed, 46 citations in OpenAlex.

  1. Article
  2. Use of a Double-Transfected System to Predict hOCT2/hMATE1-Mediated Renal Drug-Drug Interactions.Drug metabolism and disposition: the biological fate of chemicals · 2024
    Article
  3. Article
  4. Article
  5. Effect of Cimetidine on Metformin Pharmacokinetics and Endogenous Metabolite Levels in Rats.Drug metabolism and disposition: the biological fate of chemicals · 2024
    Article
  6. Article
  7. Review
  8. Review
  9. Article
  10. Article
  11. Article
  12. Drug metabolism and disposition: the biological fate of chemicals · 2021
    Article
  13. Article
  14. Characterization ofMolecular pharmacology · 2020
    Article
  15. Molecular and cellular physiology of organic cation transporter 2.American journal of physiology. Renal physiology · 2019
    Review
  16. Kinetic basis of metformin-MPP interactions with organic cation transporter OCT2.American journal of physiology. Renal physiology · 2019
    Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Jia YinDepartment of Pharmaceutics, University of Washington, Seattle, Washington.
Haichuan DuanDepartment of Pharmaceutics, University of Washington, Seattle, Washington.
Joanne WangDepartment of Pharmaceutics, University of Washington, Seattle, Washington jowang@uw.edu.
University of Washington · US

Funding

NRSA Training CoreTL1TR002318 · NCATS · UNIVERSITY OF WASHINGTON · PI Megan Moore · 2017 to 2026
$8.4M
The plasma membrane monoamine transporter (PMAT): expression and role in mIBG disposition in neuroblastomaR01GM066233 · NIGMS · UNIVERSITY OF WASHINGTON · PI WANG, JOANNE · 2002 to 2020
$5.1M
Institute of Translational Health SciencesTL1TR000422 · NCATS · UNIVERSITY OF WASHINGTON · PI DISIS, MARY L. · 2012 to 2016
$2.1M
NCATS NIH HHS TL1 TR000422NCATS NIH HHS TL1 TR002318NIGMS NIH HHS R01 GM066233
6 · The paper itself

Abstract

Renal transporter-mediated drug-drug interactions (DDIs) are of significant clinical concern, as they can adversely impact drug disposition, efficacy, and toxicity. Emerging evidence suggests that human renal organic cation transporter 2 (hOCT2) and multidrug and toxin extrusion proteins 1 and 2-K (hMATE1/2-K) exhibit substrate-dependent inhibition, but their impact on renal drug secretion and intracellular accumulation is unknown. Using metformin and atenolol as the probe substrates, we found that the classic inhibitors (e.g., cimetidine) of renal organic cation secretion were approximately 10-fold more potent for hOCT2 when atenolol was used, suggesting that atenolol is a more sensitive in vitro substrate for hOCT2 than metformin. In contrast, inhibition of hMATE1/2-K was influenced much less by the choice of substrate. Cimetidine is a much more potent inhibitor for hMATE1/2-K when metformin is the substrate but acts as an equally potent inhibitor of hOCT2 and hMATE1/2-K when atenolol is the substrate. Using hOCT2/hMATE1 double-transfected Madin-Darby canine kidney cells, we evaluated the impact of substrate-dependent inhibition on hOCT2/hMATE1-mediated transepithelial flux and intracellular drug accumulation. At clinically relevant concentrations, cimetidine dose dependently inhibited basal-to-apical flux of atenolol and metformin but impacted their intracellular accumulation differently, indicating that substrate-dependent inhibition may shift the major substrate-inhibitor interaction site between apical and basolateral transporters. Cimetidine is effective only when applied to the basal compartment. Our findings revealed the complex and dynamic nature of substrate-dependent inhibition of renal organic cation drug transporters and highlighted the importance of considering substrate-dependent inhibition in predicting transporter-mediated renal drug interaction, accumulation, and toxicity.

Indexed as

Drug InteractionsAnimalsAtenololBiological TransportCimetidineDogsHEK293 CellsHumansIntracellular SpaceKidneyMadin Darby Canine Kidney CellsMetforminOrganic Cation Transporter 2Organic Cation Transport ProteinsPharmaceutical PreparationsAtenololCimetidineMetforminOrganic Cation Transporter 2Organic Cation Transport ProteinsPharmaceutical PreparationsSLC22A2 protein, humanSLC47A1 protein, humanSLC47A2 protein, human

Identifiers

PMID27758931
PMCPMC5118648
OpenAlexW2527773738

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.